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ABSTRACT
This study evaluated the clinical and microbiolo-
gical characteristics of 16 patients who were
colonised or infected with 26 isolates of pan-
drug-resistant Pseudomonas aeruginosa (PDRPA;
intermediately-resistant or resistant to all cephalo-
sporins, piperacillin–tazobactam, aztreonam,
carbapenems, ciprofloxacin and aminoglycosides)
in a university hospital during 1999–2002. All the
isolates had colistin MICs £ 4 mg ⁄L, 19 (73%)
isolates had blaVIM-3, and 25 (96%) isolates had
class I integrons (intI). Time-kill studies for two
PDRPA blood isolates demonstrated synergism
for cefepime–amikacin after 24 h. Pulsed-field gel
electrophoresis analysis of the isolates revealed a
polyclonal nature (12 pulsotypes), although clonal
dissemination of PDRPA isolates among these
patients was also present.
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Pseudomonas aeruginosa is a major cause of no-
socomial infection, particularly among immuno-
compromised patients or patients treated in
intensive care units (ICUs) [1–5]. Anti-pseudomo-
nal b-lactams, fluoroquinolones, aminoglyco-
sides and carbapenems are used for treating
P. aeruginosa infections [1–5], and intensive use
of these antimicrobial agents has facilitated the
rapid emergence of resistance in this species
[1,6–8]. Imipenem-resistant and pan-drug-resist-
ant isolates of P. aeruginosa have been reported as
the cause of nosocomial outbreaks of infection in
ICUs and burn units in the past decade [8–10].
During the period January 1999 to December
2002, 26 pan-drug-resistant P. aeruginosa (PDRPA)
isolates, defined as isolates intermediately-resist-
ant or resistant to all antimicrobial agents avail-
able for clinical use (cephalosporins, piperacillin–
tazobactam, aztreonam, carbapenems, ciprofloxa-
cin and aminoglycosides) according to routine
disk-diffusion susceptibility results [11], were
recovered from 16 patients at National Taiwan
University Hospital, a 2000-bed hospital located in
northern Taiwan (Table 1). There were two pa-
tients who were infected or colonised with PDRPA
in 1999, four in 2000, five in 2001, and five in 2002.
All 16 patients had various underlying dis-
eases. Ten of the 16 patients acquired PDRPA
infection in an ICU. Three of the patients had
catheter-related bacteraemia, six had an indwell-
ing device associated with urinary tract infection,
four had ventilator-associated pneumonia, one
had a wound infection and multiple episodes of
catheter-related bacteraemia, and one had
nosocomial pneumonia and urinary tract infec-
tion. Each patient had received a carbapenem
(imipenem or meropenem) (six patients) or an
extended-spectrum cephalosporin (cefepime or
ceftazidime) (ten patients), either alone or in
combination with ciprofloxacin or an aminogly-
coside, before isolation of PDRPA.
The interval between admission and the first
isolation of PDRPA for the 16 patients ranged
from 2 to 290 days, with a mean of 74 days. Three
patients (patients 1, 11 and 15) had more than one
PDRPA isolate recovered from various clinical
specimens during their period of admission (three
isolates from each individual patient were iden-
tical; see below). Three patients (patients 2, 3 and
4) died before PDRPA was isolated. The remain-
ing 13 patients received cefepime or meropenem,
plus an aminoglycoside or ciprofloxacin. Seven
(43.8%) patients (patients 2–6, 13 and 14) died
within 30 days of isolation of PDRPA.
MICs of ten antimicrobial agents for the 26
isolates were determined using the agar dilution
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method [12]. These isolates were intermediately-
resistant or resistant (50%) to amikacin, and
resistant to aztreonam (27%), cefepime (12%),
ceftazidime (8%), ciprofloxacin (4%), levofloxacin
(4%), imipenem (4%) and meropenem (4%), but
not to piperacillin–tazobactam. The MIC range of
colistin was 0.5–4 mg ⁄L, with an MIC50 of 1 mg ⁄L
and an MIC90 of 4 mg ⁄L. All PDRPA isolates were
negative for the blaIMP-1, blaIMP-2, blaVIM-1, blaVIM-2
or blaVIM-4 genes [13,14]. Nineteen (73%) of the 26
PDRPA isolates harboured blaVIM-3, and 25 (96%)
had class I integrons (intI) (Table 1) [15,16]. The
blaVIM-3 gene, shown previously by sequencing to
be contained within intI, was not transferable by
conjugation.
Time-kill curves were determined for two
PDRPA isolates recovered from two patients with
bloodstream infections as described previously
[17]. Antimicrobial agents were tested alone and in
four combinations: ceftazidime, aztreonam, cefep-
ime plus amikacin, and ceftazidime plus ciprofl-
oxacin. All combinations, except the ceftazidime
Table 1. Clinical and microbiological characteristics of 16 patients with pan-drug-resistant Pseudomonas aeruginosa (n = 26)
infections
Patient Age ⁄ sex
Underlying
conditions Locationb
Isolate MIC (mg/L)
blaVIM-3 int1
PFGE
pulsotypeDesignation Source
Date (day/month/year)
of isolation (days)c Imipenem Meropenem
1a 76 ⁄M Previous
CVA, ARF
3C2 A Sputum 8 ⁄ 4 ⁄ 1999 (18) 32 32 – + I
2 78 ⁄ F Colon
cancer,
CAD, ARF
4C1 B Sputum 28 ⁄ 5 ⁄ 1999 (16) 16 16 – + II
3 69 ⁄M Lung
cancer,
previous
CVA
14A C Blood 27 ⁄ 12 ⁄ 1999 (46) 32 > 32 – – III
4 17 ⁄M AML,
post-BMT,
neutropenia
(post-C ⁄T)
4C2 D Blood 29 ⁄ 3 ⁄ 2000 (50) 16 32 – + IV
5 12 ⁄ F SLE 4C2 E Genital
discharge
24 ⁄ 4 ⁄ 2000 (120) > 32 > 32 + + V
6 57 ⁄ F DM, CRI 13D F Sputum 14 ⁄ 11 ⁄ 2000 (90) > 32 > 32 + + VI
7 70 ⁄ F Liver
cirrhosis,
MPGN
13D G Urine 19 ⁄ 12 ⁄ 2000 (49) > 32 > 32 + + VI
8 76 ⁄M CVA, BPH
with
cystofix
indwelling
4W1 H Urine 16 ⁄ 7 ⁄ 2001 (3) 16 8 + + VII
9 62 ⁄ F VHD with
CHF
14B I Sputum 1 ⁄ 8 ⁄ 2001 (88) > 32 > 32 + + VI
10 70 ⁄M DM, vocal
cord
paralysis,
tracheostomy
3C1 J Sputum 29 ⁄ 10 ⁄ 2001 (2) 16 16 – + VIII
11a 20 ⁄M Flame burn
(95% of TBSA)
3A1 K Blood 12 ⁄ 11 ⁄ 2001 (120) 8 32 + + IX
12 75 ⁄M COPD, BPH 15A L Wound 31 ⁄ 12 ⁄ 2001 (33) 16 16 + + VIII
13 25 ⁄M Flame burn,
ARF (93%
of TBSA)
12C M Urine 16 ⁄ 3 ⁄ 2002 (140) > 32 > 32 + + X
14 9 ⁄ F Flame burn
(93% of TBSA)
3A1 N Blood 5 ⁄ 6 ⁄ 2002 (70) > 32 > 32 + + XI
15a 66 ⁄M DM,
previous
TB,
cryptococcal
meningitis
3C1 O Sputum 2 ⁄ 9 ⁄ 2002 (47) > 32 > 32 + + XI
16 35 ⁄M Pemphigus
vulgaris,
steroid
use,
previous
CVA
3A1 P Urine 14 ⁄ 10 ⁄ 2002 (290) > 32 > 32 + + XII
PFGE, pulsed-field gel electrophoresis; CVA, cerebrovascular accident; ARF, acute renal failure; CAD, coronary artery disease; AML, acute myeloblastic leukaemia; BMT, bone
marrow transplantation; C ⁄T, chemotherapy; SLE, systemic lupus erythematosus; DM, diabetes mellitus; TBSA, total body surface area; CRI, chronic renal insufficiency;
MPGN, membranoproliferative glomerulonephritis; BPH, benign prostatic hypertrophy; COPD, chronic obstructive pulmonary disease; VHD, vulvular heart disease.
aMultiple isolates belonging to the same pulsotype were obtained from this patient.
bIntensive care units (3A1, 3C1, 3C2, 4C1, and 4C2) and general wards (4W1, 12C, 13B, 13D, 14A, 14B and 15A).
cIndicates intervals (days) between admission and isolation of PDRPA.
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plus ciprofloxacin combination, resulted in syner-
gism after 24 h with 0.5· the MICs for the two
PDRPA isolates. The combination regimens also
resulted in a higher rate of killing of these two
isolates over the first 2–4 h, when compared with
the most active single agent (Fig. 1). At 0.25· the
MICs, synergism after 24 h was observed only with
the cefepime plus amikacin combination.
Genotypes (pulsotypes) of the 26 isolates were
determined by pulsed-field gel electrophoresis
using restriction enzyme SpeI [17]. In total, 12
pulsotypes of PDRPA were identified among
these 16 patients. Three patients (patients 6, 7
and 9) yielded isolates of PDRPA that belonged to
the same pulsotype (VI); two of these patients had
been admitted to the same ward in 2000, while
one was admitted to a different ward in 2001. Two
patients (patients 14 and 15) who yielded isolates
that belonged to pulsotype XI were admitted to
different ICUs on the same floor of the hospital,
but 3 months apart. The same pulsotypes were
identified from each of the three patients who
yielded more than one PDRPA isolate during
their hospital stays, with an interval that ranged
from 8 days (patient 1) to 80 days (patient 11).
These findings highlight three important points.
First, although some dissemination of two of the 12
clones was observed, the high genotypic hetero-
geneity among the PDRPA isolates is indicative
of the polyclonal nature of emergence of
these resistant bacteria. Second, since the spread
of metallo-b-lactamase-producing P. aeruginosa
isolates has been reported worldwide
[13,14,16,18], the fact that most PDRPA isolates in
the present study contained blaVIM-3 supports
previous findings [13], and also suggests that
horizontal transmission of a blaVIM-3-containing
integron may have occurred between these PDRPA
isolates [16]. Further study on these PDRPA iso-
lates to elucidate the mode of transfer of blaVIM-3, as
well as other mechanisms conferring multiple drug
resistance, are ongoing. Third, the time-kill analy-
ses indicated that the cefepime plus amikacin
combination seemed to be the most favourable of
the tested options for treating infections caused by
PDRPA. However, the in-vitro data should be
validated by assessing the clinical efficacy of
various combinations of antimicrobial agents
before specific recommendations can be made to
modify existing treatment guidelines for infections
caused by PDRPA [19]. In the present study, all
PDRPA isolates had colistin MICs of £ 4 mg ⁄L,
which indicates that this agent may be an alternat-
ive choice for the treatment of PDRPA infections
[20], although this agent is currently not available
in Taiwanese hospitals.
In summary, the emergence of PDRPA may be
a harbinger of the so-called post-antibiotic era. A
stringent antibiotic control policy should be exer-
cised as part of efforts to control the emergence
and spread of these multiresistant organisms, and
strict compliance with infection control measures
is essential to reduce the likelihood of nosocomial
spread of infection.
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Fig. 1. Representative killing curves
at 0.5· and 0.25· the MICs for one of
the pan-drug-resistant Pseudomonas
aeruginosa (PDRPA) blood isolates
(isolate K1; pulsotype IX-1).
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ABSTRACT
The relatedness of 112 penicillin-non-susceptible
isolates of Streptococcus pneumoniae from Hungary
was determined by pulsed-field gel electrophor-
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